{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-020572","form_type":"8-K","ticker":"ORGO","cik":"0001661181","company_name":"Organogenesis Holdings Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.887351+00:00","generated_at":"2026-06-15T06:33:40.009379+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Organogenesis Q1 rev $107.6M (+11% YoY); raises FY2023 revenue to $454-466M","bullets":["Net revenue $107.6M, up 11% YoY; net loss $3.0M vs $0.9M loss year-ago.","Advanced Wound Care revenue $100.9M (+12% YoY); Surgical & Sports Medicine $6.7M (-4% YoY).","Adjusted EBITDA $3.8M vs $5.0M prior year; adjusted net loss $0.7M.","FY2023 guidance raised: revenue $454-466M, net income $3-11M, adjusted EBITDA $38-49M.","Cash $88.7M, debt $69.9M at March 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-020572","json":"https://secwatch.observer/filing/0000950170-23-020572.json","markdown":"https://secwatch.observer/filing/0000950170-23-020572.md","text":"https://secwatch.observer/filing/0000950170-23-020572.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661181/000095017023020572/0000950170-23-020572-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661181/000095017023020572/orgo-20230510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T06:33:40.009379+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a4b6bf336db1577068e707d2d5c6e26f00c3faf5","claim":"Organogenesis Holdings Inc. reported first quarter ended March 31, 2023 results: revenue $107.6 million, net income Net loss of $3.0 million, EPS $(0.02) per share. Guidance raised.","evidence_excerpt":"Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Financial Results Summary: • Net revenue of $107.6 million for the first quarter of 2023, an increase of $10.5 million compared to net revenue of $97.1 million for the first quarter of 2022. Net revenue for the first quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661181/000095017023020572/0000950170-23-020572-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$107.6 million"},{"label":"Net income","value":"Net loss of $3.0 million"},{"label":"EPS","value":"$(0.02) per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}